- Home
- SRZN vs ZYXI Comparison
SRZN vs ZYXI Comparison
Compare SRZN & ZYXI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRZN
- ZYXI
- Stock Information
- Founded
- SRZN 2015
- ZYXI 1996
- Country
- SRZN United States
- ZYXI United States
- Employees
- SRZN N/A
- ZYXI N/A
- Industry
- SRZN Medicinal Chemicals and Botanical Products
- ZYXI Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- SRZN Health Care
- ZYXI Health Care
- Exchange
- SRZN Nasdaq
- ZYXI Nasdaq
- Market Cap
- SRZN 76.5M
- ZYXI 66.5M
- IPO Year
- SRZN N/A
- ZYXI N/A
- Fundamental
- Price
- SRZN $9.99
- ZYXI $2.35
- Analyst Decision
- SRZN Strong Buy
- ZYXI Buy
- Analyst Count
- SRZN 2
- ZYXI 3
- Target Price
- SRZN $38.50
- ZYXI $10.25
- AVG Volume (30 Days)
- SRZN 18.2K
- ZYXI 231.1K
- Earning Date
- SRZN 05-07-2025
- ZYXI 04-29-2025
- Dividend Yield
- SRZN N/A
- ZYXI N/A
- EPS Growth
- SRZN N/A
- ZYXI N/A
- EPS
- SRZN N/A
- ZYXI 0.09
- Revenue
- SRZN $10,655,000.00
- ZYXI $192,354,000.00
- Revenue This Year
- SRZN N/A
- ZYXI N/A
- Revenue Next Year
- SRZN N/A
- ZYXI $23.16
- P/E Ratio
- SRZN N/A
- ZYXI $24.44
- Revenue Growth
- SRZN N/A
- ZYXI 4.36
- 52 Week Low
- SRZN $6.00
- ZYXI $1.93
- 52 Week High
- SRZN $18.17
- ZYXI $12.19
- Technical
- Relative Strength Index (RSI)
- SRZN 46.03
- ZYXI 37.21
- Support Level
- SRZN $9.57
- ZYXI $2.09
- Resistance Level
- SRZN $10.27
- ZYXI $2.24
- Average True Range (ATR)
- SRZN 0.65
- ZYXI 0.16
- MACD
- SRZN -0.02
- ZYXI 0.18
- Stochastic Oscillator
- SRZN 33.72
- ZYXI 94.34
About SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).
About ZYXI Zynex Inc.
Zynex Inc is engaged in the manufacturing and marketing of medical devices. It operates through one primary business segment, Electrotherapy and Pain Management Products. The business activities of the company are carried out through its subsidiaries. The company designs, manufactures, and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company operates business as one operating segment which includes two revenue types: Devices and Supplies. Its markets Zynex-manufactured products which include NexWave, NeuroMove, InWave E-Wave, and others.